On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO

Company: Moleculin Biotech, Inc. (MBRX)
Category: News

Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML). “One of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently,” Moleculin CEO Walter Klemp stated in the news release.

To view the full press release, visit: http://nnw.fm/Si6GZ

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at MD Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. Moleculin also has two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. The other portfolio targets the metabolism of tumors. For more information about the company, please visit www.moleculin.com.

More from CannabisNewsBreaks

Micronet Enertec Technologies, Inc. (NASDAQ: MICT) Receives Largest Purchase Order Since 2012; Shares Higher

India Globalization Capital, Inc. (NYSE: IGC) Management Quoted in “HIGH TIMES” Article

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Spotlighted by Technical420

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, CO
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722